Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences - September 13, 2023
13 Sep 2023
DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.
TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Date: Wednesday, September 20, 2023
Location: Virtual
Company management will participate in a fireside chat at 12:40 p.m. PT / 3:40 p.m. ET / 8:40 p.m. IST
2023 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 26, 2023
Location: New York City
Company management will participate in a fireside chat at 9:25 a.m. PT / 12:25 p.m. ET / 5:25 p.m. IST
BofA Securities 2023 CNS Therapeutics Virtual Conference
Date: Tuesday, October 3, 2023
Location: Virtual
Company management will participate in a fireside chat at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST
Live webcasts, where applicable, may be accessed via the Investors section of the Jazz Pharmaceuticals website at . A replay of the webcasts will be archived on the website for 30 days.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit
for more information.
Contacts:
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:
SOURCE Jazz Pharmaceuticals plc
Company Codes: NASDAQ-NMS:JAZZ
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.